The platform will combine immiscible phase filtration sample prep with automated amplification and detection, and is expected to have initial applications in point-of-care HIV testing in remote and resource-poor areas of the world. The company also sees the platform being used for decentralized molecular testing in more developed countries.
As part of the deal, FIND will have rights to sell the HIV test, as well as Cepheid's Xpert chlamydia and gonorrhea tests, which will be sold at a discount to the public and the not-for-profit sector in some countries.
At last week's Sample Prep 2010 meeting in Baltimore, Md., microfluidics, integration, and automation were oft-cited as future market drivers in the area of sample prep for virus, toxin, and pathogen detection.
Enigma struck the alliance with Tecan in anticipation of a fourth-quarter commercial launch of its miniaturized PCR instrument for point-of-care influenza diagnostic tests in Europe in partnership with GlaxoSmithKline.